Validation of a pre-flight algorithm to guide decision-making on the use of supplemental in-flight oxygen in patients with interstitial lung disease

<title>Extract</title> It is recommended that all interstitial lung disease (ILD) patients should be considered for a risk assessment prior to air travel due to the risk of hypobaric hypoxia [1]. The hypoxic challenge test (HCT) is a clinical tool used to assess whether in-flight oxygen supplementation is required for a patient. A decrease in PaO₂ to below 6.6 kPa or oxygen saturation (SpO₂) to below 85% during the test indicates the need to recommend supplemental in-flight oxygen, signifying a “failed HCT” [2].